Compare CRDF & FTCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDF | FTCI |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.7M | 122.4M |
| IPO Year | 2012 | 2021 |
| Metric | CRDF | FTCI |
|---|---|---|
| Price | $1.63 | $4.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $9.63 | ★ $10.80 |
| AVG Volume (30 Days) | ★ 628.6K | 143.4K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.37 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $365,993.00 | ★ $99,687,000.00 |
| Revenue This Year | N/A | $65.44 |
| Revenue Next Year | N/A | $45.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 49.61 | ★ 110.51 |
| 52 Week Low | $1.48 | $2.49 |
| 52 Week High | $4.56 | $12.75 |
| Indicator | CRDF | FTCI |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 46.70 |
| Support Level | $1.51 | $4.29 |
| Resistance Level | $1.68 | $5.23 |
| Average True Range (ATR) | 0.08 | 0.36 |
| MACD | 0.01 | 0.17 |
| Stochastic Oscillator | 38.46 | 71.02 |
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.